By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Exact Sciences today reported that its third-quarter revenues rose around 8 percent and its net loss more than tripled as the firm significantly upped its investment in R&D.

The Madison, Wis.-based molecular diagnostics firm brought in total revenues of $1.4 million for the three-month period ended Sept. 30, compared to $1.3 million for the third quarter of 2009. Nearly all of its revenues came from license fees.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.

The new Riken president outlines some of his plans for the institute.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.